|
Synonyms: CDP-835 | CDP835 | Cinqaero® | Cinqair® | JES1-39D10 | SCH55700
reslizumab is an approved drug (EMA & FDA (2016))
Compound class:
Antibody
Comment: Reslizumab is a monoclonal antibody with antiinflammatory action. It is designed to treat eosinophil-driven inflammatory conditions of the airways, skin and gastrointestinal tract [1,4].
View more information in the IUPHAR Pharmacology Education Project: reslizumab |
Classification  |
|
| Compound class | Antibody |
| Approved drug? | Yes (EMA & FDA (2016)) |
| International Nonproprietary Names |
|
| INN number | INN |
| 8106 | reslizumab |
| Synonyms |
| CDP-835 | CDP835 | Cinqaero® | Cinqair® | JES1-39D10 | SCH55700 |
| Database Links |
|
| Specialist databases | |
| IMGT/mAb-DB | 279 |
| Other databases | |
| GtoPdb PubChem SID | 249565771 |
| Search PubMed clinical trials | reslizumab |
| Search PubMed titles | reslizumab |
| Search PubMed titles/abstracts | reslizumab |
| Wikipedia | Reslizumab |
